Organization and Basis of Presentation - Narrative (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 24, 2014	May 16, 2014	Nov. 06, 2014
Significant Acquisitions and Disposals [Line Items]
Proceeds from sale of business	$ 89,624,000	$ 0	$ 0
Aggregate offering price of common stock						25,000,000
Brabant Pharma Limited [Member]
Significant Acquisitions and Disposals [Line Items]
Escrow deposit				2,000,000
Cash paid in purchase				20,000,000
Additional consideration to acquire businesses				8,718,000
Issuance of common stock in conjunction with acquisition, shares				11,995,202
Aggregate amount of contingent liabilities				95,000,000
Brabant Pharma Limited [Member] | Regulatory Milestones [Member]
Significant Acquisitions and Disposals [Line Items]
Aggregate amount of contingent liabilities				50,000,000
Brabant Pharma Limited [Member] | Sales Milestones [Member]
Significant Acquisitions and Disposals [Line Items]
Aggregate amount of contingent liabilities				45,000,000
Notes Payable, Other Payables [Member]
Significant Acquisitions and Disposals [Line Items]
Debt instrument, outstanding					7,000,000
Sumavel DosePro [Member]
Significant Acquisitions and Disposals [Line Items]
Proceeds from sale of business					85,000,000
Escrow deposit					8,500,000
Revenue from finished goods inventory					4,624,000
Sumavel DosePro [Member] | Notes Payable, Other Payables [Member]
Significant Acquisitions and Disposals [Line Items]
Debt instrument, outstanding					7,000,000
Sumavel DosePro [Member] | Purchasing Entity [Member]
Significant Acquisitions and Disposals [Line Items]
Contingent consideration, additional cash payments					$ 20,000,000